Evidence Hub

The Burden of Illness of Treatment-Induced Vasomotor Symptoms in Individuals with Breast Cancer: A Systematic Literature Review

Morga A, Shiozawa A, Todorova L, Ajmera M, Arregui M, Wissinger E

Journal of clinical medicine, 2025

6 citations

Abstract

Objective: This systematic literature review (SLR) evaluates the global burden of treatment-induced vasomotor symptoms (VMSs) in individuals with breast cancer receiving tamoxifen or aromatase inhibitors (AIs). Methods: Embase and PubMed were searched for observational and interventional studies published between January 2010 and January 2023 reporting on adults who experienced moderate to severe VMSs after tamoxifen or AI treatment for breast cancer. Epidemiological, clinical, humanistic, economic, and treatment pattern data were extracted where available. Results: Of 694 unique publications identified, 37 independent studies (22 observational and 15 interventional) were included. The prevalence or incidence of treatment-induced VMSs was reported in 17 studies. The prevalence of hot flashes ranged from 32.5% to 82.9% in observational studies, while their incidence ranged from 2% to 60.0% in interventional studies. In four studies that reported data, individuals experienced VMSs with a frequency of 2 to 20 episodes per day. There were limited data on VMS timing (within a 24 h period or in relation to treatment dosing), duration, and correlations with clinical outcomes. Age, weight gain, body mass index, ethnicity, employment intensity, and certain genetic haplotypes were identified as risk factors for VMSs; however, these factors were often reported in only one study each. Notable evidence gaps in the literature included treatment options or management strategies for…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free